 
                                                                                 
                                            Texas Capital Bancshares, Inc. Announces Quarterly Dividend for Preferred Stock DALLAS, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital Bank, and its board of directors declared a cash dividend of $14.375 per share of the 5.75% Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series B (the “Series B Preferred Stock”), equivalent to $0.359375 per depositary share, each representing a 1/40th interest in a share of the Series B Preferred Stock. The depositary shares are traded on the NASDAQ under the symbol “TCBIO.” The...
 
                                                                                 
                                                                                 
                                            Texas Capital Bancshares, Inc. Announces Third Quarter 2025 Results Third quarter 2025 ROAA of 1.30% Record-level net income of $105.2 million, record-level net income available to common stockholders of $100.9 million and record-level diluted earnings per share of $2.18 for the third quarter of 2025 Record-level Book Value and record-level Tangible Book Value(2) per share of $73.05 and $73.02, respectively Growth in capital ratios continues, achieving 12.1% CET1 and 16.1% Total Capital DALLAS, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent...
 
                                                                                 
                                            Rocky Mountain Chocolate Factory Reports Second Quarter Fiscal 2026 Financial Results Management to Host Conference Call Tomorrow at 9:00 a.m. Eastern Time DURANGO, Colo., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Rocky Mountain Chocolate Factory, Inc. (Nasdaq: RMCF) (the “Company”, “we”, “RMCF”, or “Rocky Mountain Chocolate”), America’s Chocolatier™ and a leading franchiser of a premium chocolate and confectionary retail store concept, is reporting financial and operating results for its second quarter of fiscal 2026, which ended August 31, 2025. “We’ve taken meaningful steps to transform and...
 
                                            Texas Capital Bancshares, Inc. Announces Date for Q3 2025 Operating Results DALLAS, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital Bank, today announced that it expects to issue financial results for the third quarter of 2025 after market on Wednesday, October 22, 2025. Executive management will host a conference call and webcast to discuss third quarter 2025 operating results on Wednesday, October 22, 2025, at 5:00 p.m. EDT. Participants may pre-register for the call by visiting and will receive a unique PIN number t...
 
                                            Rocky Mountain Chocolate Factory Schedules Fiscal Second Quarter 2026 Conference Call for October 14, 2025 at 9:00 a.m. ET DURANGO, Colo., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Rocky Mountain Chocolate Factory Inc. (Nasdaq: RMCF) (the “Company”, “we”, or “RMCF”), America’s Chocolatier™ and a leading franchiser of a premium chocolate and confectionary retail store concept, will host a conference call on Tuesday, October 14, 2025 at 9:00 a.m. Eastern time to discuss its fiscal second quarter 2026 results. The Company’s results will be reported in a press release prior to the call. The RMCF man...
 
                                                                                 
                                            Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) REDWOOD CITY, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 16,860 shares of common stock and restricted stock units (RSUs) for 8,430 shares of common stock to two new employees under Adverum’s 2017 Inducement Plan. These awards were approved as an inducement material to the new employees entering into ...
 
                                            Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress - Presentations Highlight the Versatility of Clearside’s SCS Microinjector® Platform for the Treatment of Multiple Retinal Diseases - - CLS-AX Trial Designs in Wet AMD and Diabetic Retinopathy to be Featured in Presentation by Dr. Sobha Sivaprasad - ALPHARETTA, Ga., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the...
 
                                            Rocky Mountain Chocolate Factory Acquires Longstanding Camarillo, California Store for Company-Owned Portfolio DURANGO, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Rocky Mountain Chocolate Factory Inc. (Nasdaq: RMCF) (the “Company”, “we”, or “RMCF”), America’s Chocolatier™ and a leading franchiser of a premium chocolate and confectionary retail store concept, today announced that it has acquired its Camarillo, California store from a franchisee. This store has delighted customers and served as a staple in the community for nearly three decades. The store first opened its doors in October 19...
 
                                            Adverum Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Pipeline Highlights - ARTEMIS Phase 3 trial enrollment exceeding expectations; driven by strong retina specialist and patient enthusiasm for a potential One And Done™ therapy for wet AMD - ARTEMIS enrollment completion expected in 1Q 2026, with topline data anticipated 1H 2027 - LUNA 2-year long-term follow-up data planned in 4Q 2025 - Announced $10 million private placement with Frazier Life Sciences REDWOOD CITY, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM...
 
                                            Adverum Biotechnologies to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that Laurent Fischer, MD, President and Chief Executive Officer, and Szilárd Kiss, MD, Distinguished Professor of Ophthalmology, Professor of Genetic Medicine and Board Member of Adverum, will participate in a fireside chat at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on Wednesday, August 13, 2025 at 9:00am EDT. A live webcast of the fireside chat...
 
                                                                                 
                                            Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada - XIPERE Now Approved for Use in Multiple Global Markets - - Continued Global Expansion and Validation of Clearside’s Suprachoroidal Space Injection Platform Featuring its Commercially Proven SCS Microinjector® - ALPHARETTA, Ga., July 23, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Health Canada has...
 
                                            Texas Capital Bancshares, Inc. Announces Quarterly Dividend for Preferred Stock DALLAS, July 21, 2025 (GLOBE NEWSWIRE) -- Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital Bank, and its board of directors declared a cash dividend of $14.375 per share of the 5.75% Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series B (the “Series B Preferred Stock”), equivalent to $0.359375 per depositary share, each representing a 1/40th interest in a share of the Series B Preferred Stock. The depositary shares are traded on the NASDAQ under the symbol “TCBIO.” The...
 
                                                                                 
                                            Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline - Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases - - CLS-AX Phase 3-Ready Asset with Global Investigator Support and FDA Alignment on Pivotal Trial Program in wet AMD - - Validated Delivery Platform with Five Commercial and Late-Stage Development Suprachoroidal Licensing Collaborations - ALPHARETTA, G...
 
    
 
            Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.